Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank
Name
12325_2025_Article_3201.pdf
Size
3.35 MB
Format
Adobe PDF
Checksum (MD5)
4b37ac2e7e8b21cbecd41027b091f632
Author(s)
Khozin, Sean
Dreyer, Nancy A.
Galante, Dominic
Liu, Raymond
Neumann, Peter
Nussbaum, Nathan
O’Shaughnessy, Joyce
Patt, Debra
Rimawi, Mothaffar
Rugo, Hope
Date Issued
May 12, 2025
Journal
Advances in Therapy
Publisher
Springer Healthcare
Citation
Khozin, S., Dreyer, N.A., Galante, D. et al. Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank. Adv Ther 42, 2973–2987 (2025).
Version
Final published version
Abstract
Complementing randomized controlled trials, real-world evidence (RWE) from observational analyses can extend clinical insights in oncology. While healthcare stakeholders have published rigorous RWE frameworks and resources, a multidisciplinary think tank was established to further advance acceptance and use of RWE in treatment decision-making, with the focus on breast cancer (while recognizing relevance in oncology more broadly). Members discussed perceptions of RWE from a clinical perspective, across domains of data, methodology, and mindset, and “calls-to-action” for stakeholders. Agreement was reached on a primary “call-to-action,” to develop clinically-relevant, patient-informed, real-world endpoints, and secondary “calls-to-action”: establish a multidisciplinary consensus forum; publish examples of unique RWE value; build upon existing frameworks and resources; and tailor an approach for exhibiting utility to guideline bodies.
MIT Department
Sloan School of Management
Terms of Use
Creative Commons Attribution-Noncommercial
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1007/s12325-025-03201-y
